BackEstrella Immunopharma- Warrants (29/09/2028) Overview
Estrella Immunopharma Inc - Warrants (29/09/2028)

Estrella Immunopharma- Warrants (29/09/2028) Return on Equity

Estrella Immunopharma- Warrants (29/09/2028) (ESLAW) has a ROE of 134.74%, above the sector sector average of -5.68%.

Get informed when a big investor buys or sells

+ Follow

ROE

134.74%

Return on Equity

134.74%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Estrella Immunopharma- Warrants (29/09/2028) (ESLAW) FAQ

The latest ROE for ESLAW is 134.74%. That is above the sector sector average of -5.68%. Investors often review this figure alongside Estrella Immunopharma- Warrants (29/09/2028)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, ESLAW currently prints 134.74% for ROE, while the sector average sits near -5.68%. That is roughly 2470.8% above the sector mean. Large gaps often invite a closer look at Estrella Immunopharma- Warrants (29/09/2028)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Estrella Immunopharma- Warrants (29/09/2028) converts resources into returns. At 134.74%, ESLAW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ESLAW's ROE (134.74%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.